Free Speech--0710
This article was originally published in RPM Report
Executive Summary
Government and industry officials discuss the new drug safety law and the fortunes of the pharmaceutical industry on the campaign trail.
You may also be interested in...
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
Running Away from Part D: No Love for New Rx Benefit on Campaign Trail
It's no surprise that the Democratic Presidential candidates are attacking Medicare Part D. But the really bad news for Big Pharma is that the Republicans don't have anything nice to say about it either. At least for now.
Trump’s Legacy Versus ‘March In’ Rights
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: